Last $24.05 USD
Change Today -0.41 / -1.68%
Volume 19.8K
As of 1:04 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Open
$24.54
Previous Close
$24.46
Day High
$24.54
Day Low
$23.84
52 Week High
02/28/14 - $32.98
52 Week Low
11/7/13 - $18.97
Market Cap
494.6M
Average Volume 10 Days
122.2K
EPS TTM
$0.93
Shares Outstanding
20.6M
EX-Date
--
P/E TM
25.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERION THERAPEUTICS INC (HPTX)

Related News

No related news articles were found.

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

54 Employees
Last Reported Date: 03/7/14
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $347.0K
Chief Legal & Compliance Officer, Senior Vice...
Total Annual Compensation: $195.9K
Compensation as of Fiscal Year 2013.

hyperion therapeutics inc (HPTX) Key Developments

Hyperion Therapeutics, Inc. Elects Theodore "Ted" Schroeder to its Board of Directors

Effective August 11, 2014, the Board of Directors of Hyperion Therapeutics, Inc. elected Theodore "Ted" Schroeder to serve as a Class III director of the company, filling a vacancy created by the resignation of David Gryska from the Board in March 2014. As a Class III director, Mr. Schroeder will serve until his re-election at the annual meeting of stockholders to be held in 2015 or until his successor is elected and qualified. At this time, Mr. Schroeder has not been appointed to a committee of the Board. Mr. Schroeder has over two decades of experience in the life sciences industry. Most recently, he was the founder of Cadence Pharmaceuticals, Inc., serving as its president and chief executive officer from inception until its acquisition by Mallinckrodt Pharmaceuticals.

Hyperion Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for Fiscal 2014

Hyperion Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company reported total revenue of $37,095,000, income from operations of $15,493,000, income before income taxes of $15,360,000, net income of $17,479,000 or $0.81 per diluted share against total revenue of $7,305,000, loss from operations of $5,681,000, income before income taxes of $25,022,000, net income of $25,022,000 or $1.17 per diluted share a year ago. Adjusted net income was $21,091,000 or $0.98 per diluted share against adjusted net loss of $4,271,000 or $0.21 per diluted share a year ago. The increase in the net product revenue for RAVICTI was primarily due to steady increase in the number of patients. As a reminder, the net income from the second quarter of last year was primarily due to a onetime gain the company recorded related to its purchase of the BUPHENYL product rights. For the six months, the company reported total revenue of $56,577,000, income from operations of $17,189,000, income before income taxes of $16,704,000, net income of $18,735,000 or $1.16 per diluted share against total revenue of $8,088,000, loss from operations of $14,749,000, income before income taxes of $16,047,000, net income of $16,047,000 or $0.80 per diluted share a year ago. Adjusted net income was $24,935,000 or $1.16 per diluted share against adjusted net loss of $12,740,000 or $0.68 per diluted share a year ago. In 2014, the company expects total net revenues to be in the range of $105 million to $110 million. The company expects amortization expense to be approximately $4 million to $5 million.

Hyperion Therapeutics, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 03:40 PM

Hyperion Therapeutics, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 03:40 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Donald J. Santel, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $24.05 USD -0.41

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies
 

Industry Analysis

HPTX

Industry Average

Valuation HPTX Industry Range
Price/Earnings 27.3x
Price/Sales 5.5x
Price/Book 3.3x
Price/Cash Flow 20.9x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit www.hyperiontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.